Previous 10 | Next 10 |
Gene therapy company bluebird bio (NASDAQ: BLUE) gave an update on the clinical trial of its treatment for sickle cell disease (SCD) showing that patients in the study have remained free of the most serious symptoms of the disease. The results suggest that Bluebird is on track to submit the ...
The following slide deck was published by bluebird bio, Inc. in conjunction with this Read more ...
Bluebird bio (NASDAQ: BLUE ) announces updated data from its ongoing Phase 1/2 clinical trial, HGB-206 , evaluating gene therapy LentiGlobin in adolescents and adults with sickle cell disease (SCD). The results were virtually presented at EHA. More news on: bluebird bio, Inc., Healthcar...
Bluebird bio (NASDAQ: BLUE ) announces new data from ongoing Phase 3 clinical trials evaluating gene therapy Zynteglo (betibeglogene autotemcel) (formerly LentiGlobin) in adolescent and adult patients with a range of genotypes of transfusion-dependent beta-thalassemia (TDT). More news on...
89% of evaluable patients (17/19) with transfusion-dependent β-thalassemia who do not have a β 0 /β 0 genotype achieved transfusion independence with 11.9 g/dL median weighted average total hemoglobin (Hb) level in HGB-207 Data from exploratory analyses of HGB-207...
99.5% reduction in annualized rate of vaso-occlusive crises (VOC) and acute chest syndrome (ACS) in Group C patients with a history of VOCs and ACS (n=14) who had at least six months follow-up At up to 24 months, no reports of serious VOC or ACS in Group C patients (n=18) with at least...
What bear market? And just like that, Regeneron's ( REGN ) bear market is gone. Years of striking out with a drug the company believed in (Praluent) or hitting a bunt single with another one it overestimated (Kevzara) have been erased with the latest surge in the stock that recently eclipsed...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
bluebird bio, Inc. (NASDAQ: BLUE) today announced that, due to the public health and safety concerns related to the novel coronavirus (COVID-19) pandemic, to support the health and well-being of its directors, employees and stockholders, the location of the Company’s 2020 Annual Meetin...
bluebird bio, Inc. (NASDAQ: BLUE) today announced that the company will host a live webcast to review new data presented at the European Hematology Association (EHA) Annual Meeting on Friday, June 12 at 8:00 am ET. Investors may listen to the call on June 12, 2020 at 8:00 am ET by dialing...
News, Short Squeeze, Breakout and More Instantly...
The downtrodden biotech space has kicked off the second half of 2022 with a boom. Hard-hit gene-editing and gene therapy companies in particular have started the back half of the year on the right foot. Underscoring this point, Bluebird Bio (NASDAQ: BLUE) stock has already risen by ...
Bluebird Bio 's (NASDAQ: BLUE) stock motored upward above 24% amid an unusually high volume of trading before pulling back to around 13.3% by noon on Tuesday, likely as a result of a short squeeze . More than 34.6% of its floating shares were held short as of June 15, which puts...